Navigation Links
Deerfield Supports Patient Care Advancing Ophthalmology Company Graybug Vision
Date:5/2/2016

NEW YORK, May 2, 2016 /PRNewswire/ -- Deerfield announced today it led the $44.5 million Series B financing of Graybug Vision, Inc. Graybug Vision is an early stage pharmaceutical company committed to developing therapies that may transform care for ocular diseases including wet age-related macular degeneration (AMD) and glaucoma.  Graybug Vision's technology was first developed at Johns Hopkins University and has been spun out into a startup venture.

Graybug Vision is developing ophthalmology products enabling potentially twice per year dosing using its novel injectable depot technology.  The company recently completed a 6 month study in animals for its lead program, GB-102, a therapy for twice-yearly treatment of wet AMD.  This preclinical study demonstrated the ability of Graybug Vision's proprietary technology to deliver a small molecule drug that blocks both VEGF and PDGF for over 6 months after a single intravitreal injection in rabbits.  The technology achieves the 6 month release profile without inflammation or toxicity after an intravitreal injection – an unprecedented result for a non-steroid drug delivered to the eye.

"We are excited to work with Graybug Vision to help it advance its therapies to market. We believe the technology developed by the Johns Hopkins founders and the Graybug Vision team has the ability to change the standard of care for patients suffering from sight threatening eye disease," stated Cameron Wheeler, PhD and Principal at Deerfield.

"We are pleased to have Deerfield as a supporter of our technology and company, and we believe the firm has significant skills which will add to our Board and development of Graybug Vision," stated Jeffrey L. Cleland, PhD, President and CEO of Graybug Vision, Inc.

About Graybug Vision

Graybug Vision is developing novel products for the treatment of ocular diseases.  Graybug Vision's technology enables the delivery of compounds to the eye up to twice per year and was co-developed by Graybug Vision founder Justin Hanes, PhD, who is the Lewis J. Ort Professor of Ophthalmology at the Wilmer Eye Institute of the Johns Hopkins University, in collaboration with Graybug Vision cofounders, and leading ophthalmology clinician-scientists from the Wilmer Eye Institute Peter A. Campochiaro, MD, and Peter J. McDonnell, MD.  Graybug Vision's lead product, GB-102, is being developed for twice a year treatment of wet AMD patients.  Graybug Vision's second product consists of compounds with intraocular pressure lowering and neuroprotection that may be administered to the subconjunctiva twice per year for the treatment of glaucoma.  For more information, please visit www.graybug.com.

About Deerfield

Deerfield is an investment management firm committed to advancing healthcare through investment, information and philanthropy.

For more information, please visit www.deerfield.com

Contacts

Deerfield Management Company
Karen Heidelberger, 212-692-7140
karenh@deerfield.com

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/deerfield-supports-patient-care-advancing-ophthalmology-company-graybug-vision-300260709.html


'/>"/>
SOURCE Deerfield Management Company
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Aprecia Pharmaceuticals Set to Advance 3D Printed Drug Pipeline with Completion of $35 Million Financing Led by Deerfield Management
2. Deerfield Leads Series A in Hallux, Inc.
3. Deerfield Management Announces Partnership with Gregory Sorensen and Deerfield Imaging
4. Deerfield Invests $20 million in Editas Medicine
5. Vital Access Receives $10 Million Financing Commitment from Deerfield
6. Alimera Sciences Announces Agreement with Deerfield Management for $50.0 Million Financing
7. Takedas Deerfield Campus Among Chicago Tribunes 2013 Top 100 Workplaces
8. Takedas Deerfield Campus Ranked Among 2013 Working Mother 100 Best Companies
9. Misonix Supports Belize Spine Surgery Mission
10. Cryoport Supports ImmunoCellular Therapeutics 120-Site Phase III Clinical Trial With Cold Chain Logistics
11. MiMedx Supports FDAs Decision to Postpone April 13th Hearing on Draft Guidance Documents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2020)... ... January 23, 2020 , ... FiteBac® Cavity ... exposed dentin tubules allowing restorative adhesives to tightly bind to the prepared dentin ... FiteBac® Cavity Cleanser with 2% K21. Cavity cleansers are intended for cleansing ...
(Date:1/23/2020)... (PRWEB) , ... January 23, 2020 , ... Please join ... she begins her term as the Society’s president for 2020. Dr. Dorbala is the ... and is an associate professor of radiology at Harvard. Over more than 20 years ...
(Date:1/23/2020)... ... , ... “It’s complicated.” The phrase may apply to some ... a person’s hand, wrist, arm and shoulder. “Which is why patients should contact ... goes wrong up or down this superhighway of interconnected bones, joints, tendons, ligaments, ...
Breaking Medicine Technology:
(Date:1/24/2020)... ... January 24, 2020 , ... SweetLeaf Stevia ... expert and best-selling nutrition author Jorge Cruise to educate consumers on losing weight ... an enthusiastic advocate of intermittent fasting, that is fat burning and boosting your ...
(Date:1/23/2020)... ... ... SignatureCare Emergency Center is set to expand to North Dallas with the opening of ... of Lewisville, on 1596 W. Main St., Lewisville, TX 75067, the new location will ... It will serve residents and businesses around Lewisville, TX, including Double Oak, Copper Canyon, ...
(Date:1/23/2020)... ... January 23, 2020 , ... ... impairment, has announced the Best Memory Care Facilities in Santa Rosa, California. The ... features and amenities. , According to the Alzheimer’s Association , 5.6 ...
(Date:1/23/2020)... ... January 23, 2020 , ... ... and services that improve workforce resilience, is presenting at the NATSAP 2020 Conference. ... advocate and resource for organizations that devote themselves to society’s need for the ...
(Date:1/23/2020)... ... January 23, 2020 , ... This week, SocialClimb ... to power the Arrowlytics platform and deliver its key performance indicators (KPIs) to ... with practice management systems to extract the data necessary to enable Arrowlytics. , ...
Breaking Medicine News(10 mins):